Journal for ImmunoTherapy of Cancer (Oct 2021)
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
- Dirk Jäger,
- Niels Halama,
- Jürgen Krauß,
- Nicolas Hohmann,
- Dirk Eulberg,
- Matthias Baumann,
- Anja Williams,
- Meggy Suarez-Carmona,
- Jutta Schreiber,
- Ulrike Pruefer,
- Anna Frömming,
- Diana Beyer,
- Jarf Ulf Jungelius,
- Aram Mangasarian
Affiliations
- Dirk Jäger
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Niels Halama
- Department of Translational Immunotherapy, German Cancer Research Centre, Heidelberg, Germany
- Jürgen Krauß
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Nicolas Hohmann
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Dirk Eulberg
- NOXXON Pharma AG, Berlin, Germany
- Matthias Baumann
- NOXXON Pharma AG, Berlin, Germany
- Anja Williams
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Meggy Suarez-Carmona
- Department of Translational Immunotherapy, German Cancer Research Centre, Heidelberg, Germany
- Jutta Schreiber
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Ulrike Pruefer
- Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany
- Anna Frömming
- NOXXON Pharma AG, Berlin, Germany
- Diana Beyer
- NOXXON Pharma AG, Berlin, Germany
- Jarf Ulf Jungelius
- NOXXON Pharma AG, Berlin, Germany
- Aram Mangasarian
- NOXXON Pharma AG, Berlin, Germany
- DOI
- https://doi.org/10.1136/jitc-2021-002505
- Journal volume & issue
-
Vol. 9,
no. 10
Abstract
No abstracts available.
